Nabriva Therapeutics (NASDAQ:NBRV) Coverage Initiated by Analysts at StockNews.com

Research analysts at StockNews.com began coverage on shares of Nabriva Therapeutics (NASDAQ:NBRV) in a research note issued on Wednesday. The brokerage set a “hold” rating on the biotechnology company’s stock.

Nabriva Therapeutics Price Performance

The company has a debt-to-equity ratio of 0.12, a current ratio of 0.85 and a quick ratio of 0.52. The firm has a market cap of $45.46 million, a PE ratio of -0.07 and a beta of 1.53. Nabriva Therapeutics has a 52-week low of $1.22 and a 52-week high of $8.45. The stock has a fifty day simple moving average of $0.14 and a two-hundred day simple moving average of $0.61.

Institutional Trading of Nabriva Therapeutics

A hedge fund recently raised its stake in Nabriva Therapeutics stock. Renaissance Technologies LLC boosted its position in shares of Nabriva Therapeutics plc (NASDAQ:NBRV) by 102.1% in the second quarter, according to the company in its most recent filing with the SEC. The firm owned 795,938 shares of the biotechnology company’s stock after acquiring an additional 402,144 shares during the quarter. Renaissance Technologies LLC owned about 0.13% of Nabriva Therapeutics worth $145,000 at the end of the most recent reporting period. 0.27% of the stock is owned by hedge funds and other institutional investors.

About Nabriva Therapeutics

Nabriva Therapeutics plc, a biopharmaceutical company, engages in the development and commercialization of novel anti-infective agents to treat serious infections. The company's product includes SIVEXTRO, an oxazolidinone-class antibacterial for the treatment of acute bacterial skin and skin structure infection (ABSSSI); and XENLETA, a semi-synthetic pleuromutilin antibiotic for oral and IV administration.